Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

British Journal of Cancer

Topics

Biology

Biochemistry

Molecular Biology

Pathology And Forensic Medicine

Neurotrophin

Show all topics

DOI

10.1038/s41416-024-02760-1

License

CC-BY

Other Formats

PDF